Received Feb 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | 4N22 | IM |
Priorix shot was administered back on 2 February 2026 to a female patient Intramuscularly instead of the recommended Subcutaneous route; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of subcutaneous injection formulation administered by other route in a female patient who received MMR (Priorix) (batch number 4N22, expiry date 13-SEP-2026) for prophylaxis. On 02-FEB-2026, the patient received the 1st dose of Priorix (intramuscular). On 02-FEB-2026, an unknown time after receiving Priorix, the patient experienced subcutaneous injection formulation administered by other route (Verbatim: Priorix shot was administered back on 2 February 2026 to a female patient Intramuscularly instead of the recommended Subcutaneous route). The outcome of the subcutaneous injection formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date: 06-FEB-2026 The reporter wanted to know if effectiveness was the same and if revaccination was needed. The batch number was not provided and a request for this information has been made.